BTIG Research Lowers Delcath Systems (NASDAQ:DCTH) Price Target to $19.00

Delcath Systems (NASDAQ:DCTH) had its price target reduced by research analysts at BTIG Research from $23.00 to $19.00 in a report released on Thursday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price suggests a potential upside of 113.48% from the stock’s current price.

Other analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Delcath Systems in a research note on Friday, January 9th. Stephens decreased their target price on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Delcath Systems in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Delcath Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Delcath Systems Stock Performance

DCTH stock opened at $8.90 on Thursday. The company has a 50 day moving average price of $9.98 and a two-hundred day moving average price of $10.20. The stock has a market capitalization of $314.26 million, a P/E ratio of 127.14 and a beta of 0.37. Delcath Systems has a one year low of $8.12 and a one year high of $18.23.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. The business had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $20.35 million. Delcath Systems had a return on equity of 2.70% and a net margin of 3.17%. Research analysts forecast that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Delcath Systems announced that its board has initiated a stock repurchase program on Thursday, November 20th that allows the company to repurchase $25.00 million in shares. This repurchase authorization allows the company to reacquire up to 8.6% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

Institutional Trading of Delcath Systems

A number of institutional investors have recently added to or reduced their stakes in DCTH. Deutsche Bank AG increased its holdings in Delcath Systems by 5.4% in the 4th quarter. Deutsche Bank AG now owns 24,162 shares of the company’s stock valued at $244,000 after purchasing an additional 1,248 shares in the last quarter. California State Teachers Retirement System acquired a new stake in shares of Delcath Systems in the second quarter valued at about $26,000. Intech Investment Management LLC raised its holdings in shares of Delcath Systems by 13.1% during the 4th quarter. Intech Investment Management LLC now owns 17,595 shares of the company’s stock valued at $178,000 after buying an additional 2,035 shares during the period. AWM Investment Company Inc. lifted its position in Delcath Systems by 3.9% during the 4th quarter. AWM Investment Company Inc. now owns 60,000 shares of the company’s stock worth $606,000 after acquiring an additional 2,279 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Delcath Systems in the third quarter valued at approximately $29,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems News Roundup

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Company reported Q4 and full‑year 2025 results with Q4 revenue of $20.7M and full‑year revenue of $85.2M; EPS of ($0.05) beat consensus by $0.01 — evidence of improving commercial execution. BusinessWire Release
• Positive Sentiment: Management is targeting at least $100M in revenue for 2026 and plans to expand to ~40 treatment centers, signaling a clear growth roadmap and potential material revenue upside if execution continues. Seeking Alpha
• Neutral Sentiment: Company updated FY‑2026 revenue guidance to ~$100.0M (effectively in line with consensus ~100.1M); guidance confirms the growth target but leaves little upside vs. street estimates absent faster center rollout or higher per‑center revenue. MarketBeat Earnings
• Neutral Sentiment: BTIG cut its price target from $23 to $19 but kept a “buy” rating—still implying substantial upside from current levels, though the downgrade signals more conservative near‑term expectations from at least one sell‑side shop. Street Insider

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.